

Sylvain Lehmann

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/534767/publications.pdf>

Version: 2024-02-01

268
papers

13,645
citations

21215

62
h-index

31191

106
g-index

299
all docs

299
docs citations

299
times ranked

15358
citing authors

#	ARTICLE	IF	CITATIONS
1	Quantifying RNA modifications by mass spectrometry: a novel source of biomarkers in oncology. <i>Critical Reviews in Clinical Laboratory Sciences</i> , 2022, 59, 1-18.	2.7	14
2	Hypoxemia increases blood-brain barrier permeability during extreme apnea in humans. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2022, 42, 1120-1135.	2.4	18
3	Comparison of cerebrospinal fluid tau, ptau(181), synuclein, and 14-3-3 for the detection of Creutzfeldt-Jakob disease in clinical practice. <i>Journal of Neural Transmission</i> , 2022, 129, 133-139.	1.4	6
4	The A β ¹⁻⁴² /A β ¹⁻⁴⁰ ratio in CSF is more strongly associated to tau markers and clinical progression than A β ¹⁻⁴² alone. <i>Alzheimer's Research and Therapy</i> , 2022, 14, 20.	3.0	18
5	Plasma amyloid beta predicts conversion to dementia in subjects with mild cognitive impairment: The BALTAZAR study. <i>Alzheimer's and Dementia</i> , 2022, 18, 2537-2550.	0.4	21
6	Deciphering Black Extrinsic Tooth Stain Composition in Children Using Metaproteomics. <i>ACS Omega</i> , 2022, 7, 8258-8267.	1.6	5
7	Blood amyloid and tau biomarkers as predictors of cerebrospinal fluid profiles. <i>Journal of Neural Transmission</i> , 2022, 129, 231-237.	1.4	7
8	Clinical reporting following the quantification of cerebrospinal fluid biomarkers in Alzheimer's disease: An international overview. <i>Alzheimer's and Dementia</i> , 2022, 18, 1868-1879.	0.4	26
9	Immunoassay and Mass Spectrometry Methods for Tau Protein Quantification in the Cerebrospinal Fluid. <i>NeuroMethods</i> , 2021, , 71-85.	0.2	0
10	Impact of treating iron deficiency, diagnosed according to hepcidin quantification, on outcomes after a prolonged ICU stay compared to standard care: a multicenter, randomized, single-blinded trial. <i>Critical Care</i> , 2021, 25, 62.	2.5	28
11	Sensitive protein misfolding cyclic amplification of sporadic Creutzfeldt-Jakob disease prions is strongly seed and substrate dependent. <i>Scientific Reports</i> , 2021, 11, 4058.	1.6	10
12	Tau protein in cerebrospinal fluid: a novel biomarker of the time of death?. <i>International Journal of Legal Medicine</i> , 2021, 135, 2081-2089.	1.2	7
13	The potential impact of salivary peptides in periodontitis. <i>Critical Reviews in Clinical Laboratory Sciences</i> , 2021, 58, 479-492.	2.7	14
14	NFL strongly correlates with TNF-R1 in the plasma of AD patients, but not with cognitive decline. <i>Scientific Reports</i> , 2021, 11, 10283.	1.6	11
15	Use of plasma biomarkers for AT(N) classification of neurodegenerative dementias. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2021, 92, 1206-1214.	0.9	30
16	Cytokines as new biomarkers of skin wound vitality. <i>International Journal of Legal Medicine</i> , 2021, 135, 2537-2545.	1.2	14
17	Serum glial fibrillary acidic protein is a predictor of brain metastases in patients with metastatic breast cancer. <i>International Journal of Cancer</i> , 2021, 149, 1605-1618.	2.3	8
18	Phosphorylated tau181 in plasma as a potential biomarker for Alzheimer's disease in adults with Down syndrome. <i>Nature Communications</i> , 2021, 12, 4304.	5.8	33

#	ARTICLE	IF	CITATIONS
19	Analytical comparison of ELISA and mass spectrometry for quantification of serum hepcidin in critically ill patients. <i>Bioanalysis</i> , 2021, 13, 1029-1035.	0.6	6
20	Association of Apolipoprotein E ϵ 4 Allele With Clinical and Multimodal Biomarker Changes of Alzheimer Disease in Adults With Down Syndrome. <i>JAMA Neurology</i> , 2021, 78, 937.	4.5	32
21	Deconstructing Alzheimer's Disease: How to Bridge the Gap between Experimental Models and the Human Pathology?. <i>International Journal of Molecular Sciences</i> , 2021, 22, 8769.	1.8	12
22	Concussion history in rugby union players is associated with depressed cerebrovascular reactivity and cognition. <i>Scandinavian Journal of Medicine and Science in Sports</i> , 2021, 31, 2291-2299.	1.3	7
23	Variation of human salivary alpha-amylase proteoforms in three stimulation models. <i>Clinical Oral Investigations</i> , 2020, 24, 475-486.	1.4	7
24	Detection of amyloid beta peptides in body fluids for the diagnosis of Alzheimer's disease: Where do we stand?. <i>Critical Reviews in Clinical Laboratory Sciences</i> , 2020, 57, 99-113.	2.7	24
25	Cerebrospinal fluid A beta 1-40 peptides increase in Alzheimer's disease and are highly correlated with phospho-tau in control individuals. <i>Alzheimer's Research and Therapy</i> , 2020, 12, 123.	3.0	33
26	Hepcidin and ferritin levels in restless legs syndrome: a case-control study. <i>Scientific Reports</i> , 2020, 10, 11914.	1.6	21
27	The importance of an integrated genotype-phenotype strategy to unravel the molecular bases of titinopathies. <i>Neuromuscular Disorders</i> , 2020, 30, 877-887.	0.3	18
28	Age and the association between apolipoprotein E genotype and Alzheimer disease: A cerebrospinal fluid biomarker-based case-control study. <i>PLoS Medicine</i> , 2020, 17, e1003289.	3.9	39
29	Editorial: Proteomics as a Tool for Biomarker and Drug Target Discovery: Improving the Diagnosis and Treatment of Neurodegenerative Diseases. <i>Frontiers in Aging Neuroscience</i> , 2020, 12, 232.	1.7	1
30	MALDI-TOF IP-MS quantification of plasma amyloid peptides in Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2020, 16, e047112.	0.4	2
31	Cerebrospinal Fluid and Plasma Biomarkers do not Differ in the Presenile and Late-Onset Behavioral Variants of Frontotemporal Dementia. <i>Journal of Alzheimer's Disease</i> , 2020, 74, 903-911.	1.2	9
32	Gravitational Transitions Increase Posterior Cerebral Perfusion and Systemic Oxidative-nitrosative Stress: Implications for Neurovascular Unit Integrity. <i>Neuroscience</i> , 2020, 441, 142-160.	1.1	9
33	Cerebrospinal fluid phospho-tau T217 outperforms T181 as a biomarker for the differential diagnosis of Alzheimer's disease and PET amyloid-positive patient identification. <i>Alzheimer's Research and Therapy</i> , 2020, 12, 26.	3.0	138
34	A soluble phosphorylated tau signature links tau, amyloid and the evolution of stages of dominantly inherited Alzheimer's disease. <i>Nature Medicine</i> , 2020, 26, 398-407.	15.2	351
35	Clinical and biomarker changes of Alzheimer's disease in adults with Down syndrome: a cross-sectional study. <i>Lancet</i> , The, 2020, 395, 1988-1997.	6.3	164
36	Efficient extraction of intact HSA-A β peptide complexes from sera: Toward albuminome biomarker identification. <i>Talanta</i> , 2020, 216, 121002.	2.9	4

#	ARTICLE	IF	CITATIONS
37	Correlation between Bioassay and Protein Misfolding Cyclic Amplification for Variant Creutzfeldt-Jakob Disease Decontamination Studies. <i>MSphere</i> , 2020, 5, .	1.3	20
38	Peripheral Blood and Salivary Biomarkers of Bloodâ€“Brain Barrier Permeability and Neuronal Damage: Clinical and Applied Concepts. <i>Frontiers in Neurology</i> , 2020, 11, 577312.	1.1	36
39	Title is missing!. , 2020, 17, e1003289.		0
40	Title is missing!. , 2020, 17, e1003289.		0
41	Title is missing!. , 2020, 17, e1003289.		0
42	Title is missing!. , 2020, 17, e1003289.		0
43	Title is missing!. , 2020, 17, e1003289.		0
44	Title is missing!. , 2020, 17, e1003289.		0
45	Title is missing!. , 2020, 17, e1003289.		0
46	In Vivo Large-Scale Mapping of Protein Turnover in Human Cerebrospinal Fluid. <i>Analytical Chemistry</i> , 2019, 91, 15500-15508.	3.2	6
47	A Clinico-Radiological Study of Cerebral Amyloid Angiopathy-Related Inflammation. <i>Cerebrovascular Diseases</i> , 2019, 48, 38-44.	0.8	19
48	Generation of induced pluripotent stem cells (IRMBi001-A) from an Alzheimer's disease patient carrying a G217D mutation in the PSEN1 gene. <i>Stem Cell Research</i> , 2019, 34, 101381.	0.3	7
49	SILK studies â€” capturing the turnover of proteins linked to neurodegenerative diseases. <i>Nature Reviews Neurology</i> , 2019, 15, 419-427.	4.9	37
50	Stable Isotope Labeling Kinetics in CNS Translational Medicine: Introduction to SILK Technology. <i>Handbook of Behavioral Neuroscience</i> , 2019, 29, 173-190.	0.7	0
51	Biochemical markers of time since death in cerebrospinal fluid: A first step towardsâ€œForensomicsâ€œ. <i>Critical Reviews in Clinical Laboratory Sciences</i> , 2019, 56, 274-286.	2.7	8
52	Advantages and disadvantages of the use of the CSF Amyloid Î² (AÎ²) 42/40 ratio in the diagnosis of Alzheimerâ€™s Disease. <i>Alzheimer's Research and Therapy</i> , 2019, 11, 34.	3.0	325
53	Intact Protein Analysis by LC-MS for Characterizing Biomarkers in Cerebrospinal Fluid. <i>Methods in Molecular Biology</i> , 2019, 1959, 163-172.	0.4	0
54	Longitudinal cerebrospinal fluid biomarker trajectories along the Alzheimer's disease continuum in the BIOMARKAPD study. <i>Alzheimer's and Dementia</i> , 2019, 15, 742-753.	0.4	82

#	ARTICLE	IF	CITATIONS
55	Dental stem cells as a promising source for cell therapies in neurological diseases. <i>Critical Reviews in Clinical Laboratory Sciences</i> , 2019, 56, 170-181.	2.7	9
56	Cell-based therapy against prion diseases. <i>Current Opinion in Pharmacology</i> , 2019, 44, 8-14.	1.7	4
57	Impact of CSF storage volume on the analysis of Alzheimer's disease biomarkers on an automated platform. <i>Clinica Chimica Acta</i> , 2019, 490, 98-101.	0.5	17
58	Reduced brain amyloid burden in elderly patients with narcolepsy type 1. <i>Annals of Neurology</i> , 2019, 85, 74-83.	2.8	18
59	Cerebrospinal fluid chitinase-3-like protein 1 level is not an independent predictive factor for the risk of clinical conversion in radiologically isolated syndrome. <i>Multiple Sclerosis Journal</i> , 2019, 25, 669-677.	1.4	28
60	The prognostic value of the τ protein serum level in metastatic breast cancer patients and its correlation with brain metastases. <i>BMC Cancer</i> , 2019, 19, 110.	1.1	20
61	Plasma amyloid levels within the Alzheimer's process and correlations with central biomarkers. <i>Alzheimer's and Dementia</i> , 2018, 14, 858-868.	0.4	103
62	Nano-flow vs standard-flow: Which is the more suitable LC/MS method for quantifying hepcidin-25 in human serum in routine clinical settings?. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2018, 1086, 110-117.	1.2	6
63	Association between serum hepcidin level and restless legs syndrome. <i>Movement Disorders</i> , 2018, 33, 618-627.	2.2	25
64	Cerebrospinal Fluid, MRI, and Florbetaben-PET in Cerebral Amyloid Angiopathy-Related Inflammation. <i>Journal of Alzheimer's Disease</i> , 2018, 61, 1107-1117.	1.2	14
65	Assessing a multiplex-targeted proteomics approach for the clinical diagnosis of periodontitis using saliva samples. <i>Bioanalysis</i> , 2018, 10, 35-45.	0.6	12
66	Cerebrospinal fluid Alzheimer biomarkers can be useful for discriminating dementia with Lewy bodies from Alzheimer's disease at the prodromal stage. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2018, 89, 467-475.	0.9	30
67	White paper by the Society for CSF Analysis and Clinical Neurochemistry: Overcoming barriers in biomarker development and clinical translation. <i>Alzheimer's Research and Therapy</i> , 2018, 10, 30.	3.0	40
68	Identification of multiple proteoforms biomarkers on clinical samples by routine Top-Down approaches. <i>Data in Brief</i> , 2018, 18, 1013-1021.	0.5	12
69	Data from a targeted proteomics approach to discover biomarkers in saliva for the clinical diagnosis of periodontitis. <i>Data in Brief</i> , 2018, 18, 294-299.	0.5	13
70	Towards a routine application of Top-Down approaches for label-free discovery workflows. <i>Journal of Proteomics</i> , 2018, 175, 12-26.	1.2	17
71	Neuropathology of iatrogenic Creutzfeldt-Jakob disease and immunoassay of French cadaver-sourced growth hormone batches suggest possible transmission of tauopathy and long incubation periods for the transmission of A β pathology. <i>Acta Neuropathologica</i> , 2018, 135, 201-212.	3.9	71
72	Sample Pooling and Inflammation Linked to the False Selection of Biomarkers for Neurodegenerative Diseases in Top-Down Proteomics: A Pilot Study. <i>Frontiers in Molecular Neuroscience</i> , 2018, 11, 477.	1.4	20

#	ARTICLE	IF	CITATIONS
73	Impact of biological matrix on inflammatory protein biomarker quantification based on targeted mass spectrometry. <i>Bioanalysis</i> , 2018, 10, 1383-1399.	0.6	5
74	Hepcidin: immunoanalytic characteristics. <i>Annales De Biologie Clinique</i> , 2018, 76, 705-715.	0.2	0
75	Interlaboratory validation of cerebrospinal fluid β -synuclein quantification in the diagnosis of sporadic Creutzfeldt-Jakob disease. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2018, 10, 461-470.	1.2	7
76	Somatostatin and Neuropeptide Y in Cerebrospinal Fluid: Correlations With Amyloid Peptides $A\beta_{1-42}$ and Tau Proteins in Elderly Patients With Mild Cognitive Impairment. <i>Frontiers in Aging Neuroscience</i> , 2018, 10, 297.	1.7	10
77	Diagnosis of Methionine/Valine Variant Creutzfeldt-Jakob Disease by Protein Misfolding Cyclic Amplification. <i>Emerging Infectious Diseases</i> , 2018, 24, 1364-1366.	2.0	27
78	Plasma and CSF biomarkers for the diagnosis of Alzheimer's disease in adults with Down syndrome: a cross-sectional study. <i>Lancet Neurology</i> , The, 2018, 17, 860-869.	4.9	140
79	What sample preparation should be chosen for targeted MS monoclonal antibody quantification in human serum?. <i>Bioanalysis</i> , 2018, 10, 723-735.	0.6	12
80	Regulatory context and validation of assays for clinical mass spectrometry proteomics (cMSP) methods. <i>Critical Reviews in Clinical Laboratory Sciences</i> , 2018, 55, 346-358.	2.7	9
81	Alzheimer's Disease: Advances in Drug Development. <i>Journal of Alzheimer's Disease</i> , 2018, 65, 3-13.	1.2	45
82	Relevance of $A\beta_{42/40}$ Ratio for Detection of Alzheimer Disease Pathology in Clinical Routine: The PLMR Scale. <i>Frontiers in Aging Neuroscience</i> , 2018, 10, 138.	1.7	59
83	Cerebral Amyloid Angiopathy and Cerebral Amyloid Angiopathy-Related Inflammation: Comparison of Hemorrhagic and DWI MRI Features. <i>Journal of Alzheimer's Disease</i> , 2018, 64, 1113-1121.	1.2	17
84	Lithium as a disease-modifying agent for prion diseases. <i>Translational Psychiatry</i> , 2018, 8, 163.	2.4	9
85	Relevance of Follow-Up in Patients with Core Clinical Criteria for Alzheimer Disease and Normal CSF Biomarkers. <i>Current Alzheimer Research</i> , 2018, 15, 691-700.	0.7	5
86	Clinical mass spectrometry proteomics (cMSP) for medical laboratory: What does the future hold?. <i>Clinica Chimica Acta</i> , 2017, 467, 51-58.	0.5	29
87	Characterizing Deep White Matter Hyperintensities in Patients with Symptomatic Isolated Cortical Superficial Siderosis. <i>Journal of Stroke and Cerebrovascular Diseases</i> , 2017, 26, 465-469.	0.7	1
88	Quantification of hepcidin-25 in human cerebrospinal fluid using LC-MS/MS. <i>Bioanalysis</i> , 2017, 9, 337-347.	0.6	12
89	Added value of hepcidin quantification for the diagnosis and follow-up of anemia-related diseases. <i>Annales De Biologie Clinique</i> , 2017, 75, 9-18.	0.2	3
90	Cerebrospinal fluid levels of orexin-A and histamine, and sleep profile within the Alzheimer process. <i>Neurobiology of Aging</i> , 2017, 53, 59-66.	1.5	76

#	ARTICLE	IF	CITATIONS
91	Impurity determination for hepcidin by liquid chromatography-high resolution and ion mobility mass spectrometry for the value assignment of candidate primary calibrators. <i>Analytical and Bioanalytical Chemistry</i> , 2017, 409, 2559-2567.	1.9	16
92	Clinical perspectives of dried blood spot protein quantification using mass spectrometry methods. <i>Critical Reviews in Clinical Laboratory Sciences</i> , 2017, 54, 173-184.	2.7	19
93	Comparison of HbA1c detection in whole blood and dried blood spots using an automated ion-exchange HPLC system. <i>Bioanalysis</i> , 2017, 9, 427-434.	0.6	14
94	Isolation of Exosomes and Microvesicles from Cell Culture Systems to Study Prion Transmission. <i>Methods in Molecular Biology</i> , 2017, 1545, 153-176.	0.4	25
95	Impact of iron deficiency diagnosis using hepcidin mass spectrometry dosage methods on hospital stay and costs after a prolonged ICU stay: Study protocol for a multicentre, randomised, single-blinded medico-economic trial. <i>Anaesthesia, Critical Care & Pain Medicine</i> , 2017, 36, 391-396.	0.6	9
96	Multicenter Analytical Validation of Aβ ₄₀ Immunoassays. <i>Frontiers in Neurology</i> , 2017, 8, 310.	1.1	10
97	Looking for new biomarkers of skin wound vitality with a cytokine-based multiplex assay: preliminary study. <i>Annales De Biologie Clinique</i> , 2017, 75, 53-60.	0.2	3
98	Reform of the outside nomenclature biomedical tests in France: a two year review. <i>Annales De Biologie Clinique</i> , 2017, 75, 365-365.	0.2	0
99	Editorial: Biomarkers of Alzheimer's Disease: The Present and the Future. <i>Frontiers in Neurology</i> , 2016, 7, 158.	1.1	16
100	Rapid and Highly Sensitive Detection of Variant Creutzfeldt - Jakob Disease Abnormal Prion Protein on Steel Surfaces by Protein Misfolding Cyclic Amplification: Application to Prion Decontamination Studies. <i>PLoS ONE</i> , 2016, 11, e0146833.	1.1	24
101	Cerebrospinal Fluid Alzheimer's Disease Biomarkers in Isolated Supratentorial Cortical Superficial Siderosis. <i>Journal of Alzheimer's Disease</i> , 2016, 54, 1291-1295.	1.2	16
102	From radioimmunoassay to mass spectrometry: a new method to quantify orexin-A (hypocretin-1) in cerebrospinal fluid. <i>Scientific Reports</i> , 2016, 6, 25162.	1.6	36
103	Differential Mass Spectrometry Profiles of Tau Protein in the Cerebrospinal Fluid of Patients with Alzheimer's Disease, Progressive Supranuclear Palsy, and Dementia with Lewy Bodies. <i>Journal of Alzheimer's Disease</i> , 2016, 51, 1033-1043.	1.2	104
104	01-05-04: PROFILING OF INTACT PROTEINS IN THE CSF OF ALZHEIMER'S DISEASE PATIENTS USING TOP DOWN CLINICAL PROTEOMICS (TDCP): A NEW APPROACH GIVING ACCESS TO ISOFORM SPECIFIC INFORMATION OF NEURODEGENERATIVE BIOMARKERS. <i>Alzheimer's and Dementia</i> , 2016, 12, P183.	0.4	1
105	Cerebrospinal Fluid Alzheimer's Disease Biomarkers in Cerebral Amyloid Angiopathy-Related Inflammation. <i>Journal of Alzheimer's Disease</i> , 2016, 50, 759-764.	1.2	23
106	Comparison of Different Matrices as Potential Quality Control Samples for Neurochemical Dementia Diagnostics. <i>Journal of Alzheimer's Disease</i> , 2016, 52, 51-64.	1.2	18
107	Proteomic profile of cerebrospinal fluid in patients with multiple sclerosis using two dimensional gel electrophoresis. <i>British Journal of Biomedical Science</i> , 2016, 73, 143-146.	1.2	4
108	Development of new quantitative mass spectrometry and semi-automatic isofocusing methods for the determination of Apolipoprotein E typing. <i>Clinica Chimica Acta</i> , 2016, 454, 33-38.	0.5	19

#	ARTICLE	IF	CITATIONS
109	Amyloid imaging by 18F-florbetaben PET in a patient with isolated microbleeds and leukoencephalopathy. <i>Acta Neurologica Belgica</i> , 2016, 116, 623-625.	0.5	0
110	Absolute quantification of 35 plasma biomarkers in human saliva using targeted MS. <i>Bioanalysis</i> , 2016, 8, 43-53.	0.6	22
111	Human S100A10 plays a crucial role in the acquisition of the endometrial receptivity phenotype. <i>Cell Adhesion and Migration</i> , 2016, 10, 282-298.	1.1	32
112	Tau Protein Quantification in Human Cerebrospinal Fluid by Targeted Mass Spectrometry at High Sequence Coverage Provides Insights into Its Primary Structure Heterogeneity. <i>Journal of Proteome Research</i> , 2016, 15, 667-676.	1.8	91
113	Quiescin-sulfhydryl oxidase inhibits prion formation in vitro. <i>Aging</i> , 2016, 8, 3419-3429.	1.4	2
114	MACVIA-LR (FIGHTING CHRONIC DISEASES FOR ACTIVE AND HEALTHY AGEING IN LANGUEDOC-ROUSSILLON): A SUCCESS STORY OF THE EUROPEAN INNOVATION PARTNERSHIP ON ACTIVE AND HEALTHY AGEING. <i>Journal of Frailty & Aging, the</i> , 2016, 5, 1-9.	0.8	8
115	O5-05-04: Large scale proteomics exploration of human cerebrospinal fluid (CSF) in Alzheimer's disease patients using stable isotope labeling amino acid in vivo (SILAV). , 2015, 11, P326-P326.		0
116	Analytical challenges related to the use of biomarker ratios for the biological diagnosis of Alzheimer's disease. <i>Clinical Chemistry and Laboratory Medicine</i> , 2015, 53, e175-7.	1.4	1
117	Late-onset behavioral variant of frontotemporal lobar degeneration versus Alzheimer's disease: Interest of cerebrospinal fluid biomarker ratios. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2015, 1, 371-379.	1.2	13
118	Cerebrospinal fluid amyloid- β 42/40 ratio in clinical setting of memory centers: a multicentric study. <i>Alzheimer's Research and Therapy</i> , 2015, 7, 30.	3.0	101
119	Stable Isotope Labeling by Amino acid <i>in Vivo</i> (SILAV): a new method to explore protein metabolism. <i>Rapid Communications in Mass Spectrometry</i> , 2015, 29, 1917-1925.	0.7	10
120	Central Nervous System and Peripheral Inflammatory Processes in Alzheimer's Disease: Biomarker Profiling Approach. <i>Frontiers in Neurology</i> , 2015, 6, 181.	1.1	44
121	The Central Biobank and Virtual Biobank of BIOMARKAPD: A Resource for Studies on Neurodegenerative Diseases. <i>Frontiers in Neurology</i> , 2015, 6, 216.	1.1	36
122	Antibody-free quantification of seven tau peptides in human CSF using targeted mass spectrometry. <i>Frontiers in Neuroscience</i> , 2015, 9, 302.	1.4	34
123	Efficient inhibition of infectious prions multiplication and release by targeting the exosomal pathway. <i>Cellular and Molecular Life Sciences</i> , 2015, 72, 4409-4427.	2.4	47
124	What is the potential of dried matrix spot sampling for cerebrospinal fluid analysis?. <i>Bioanalysis</i> , 2015, 7, 2849-2851.	0.6	1
125	Operational definition of Active and Healthy Ageing (AHA): A conceptual framework. <i>Journal of Nutrition, Health and Aging</i> , 2015, 19, 955-960.	1.5	85
126	Developmental determinants in non-communicable chronic diseases and ageing. <i>Thorax</i> , 2015, 70, 595-597.	2.7	45

#	ARTICLE	IF	CITATIONS
127	Conversion from clinically isolated syndrome to multiple sclerosis: A large multicentre study. <i>Multiple Sclerosis Journal</i> , 2015, 21, 1013-1024.	1.4	249
128	Chitinase 3-like proteins as diagnostic and prognostic biomarkers of multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2015, 21, 1251-1261.	1.4	131
129	Operative definition of active and healthy ageing (AHA): Meeting report. Montpellier October 2014. <i>European Geriatric Medicine</i> , 2015, 6, 196-200.	1.2	18
130	Arsenic trioxide-based therapy of relapsed acute promyelocytic leukemia: registry results from the European LeukemiaNet. <i>Leukemia</i> , 2015, 29, 1084-1091.	3.3	70
131	Can we rely only on ratios of cerebrospinal fluid biomarkers for AD biological diagnosis?. <i>Alzheimer's and Dementia</i> , 2015, 11, 1125-1126.	0.4	8
132	Quantitative detection of amyloid- β peptides by mass spectrometry: state of the art and clinical applications. <i>Clinical Chemistry and Laboratory Medicine</i> , 2015, 53, 1483-93.	1.4	30
133	Prion strains are differentially released through the exosomal pathway. <i>Cellular and Molecular Life Sciences</i> , 2015, 72, 1185-1196.	2.4	46
134	Systemic Delivery of siRNA Down Regulates Brain Prion Protein and Ameliorates Neuropathology in Prion Disorder. <i>PLoS ONE</i> , 2014, 9, e88797.	1.1	16
135	Hypocretin and brain β -amyloid peptide interactions in cognitive disorders and narcolepsy. <i>Frontiers in Aging Neuroscience</i> , 2014, 6, 119.	1.7	43
136	Prion diseases and adult neurogenesis: How do prions counteract the brain's endogenous repair machinery?. <i>Prion</i> , 2014, 8, 240-246.	0.9	11
137	A diagnostic scale for Alzheimer's disease based on cerebrospinal fluid biomarker profiles. <i>Alzheimer's Research and Therapy</i> , 2014, 6, 38.	3.0	44
138	Impact of harmonization of collection tubes on Alzheimer's disease diagnosis. , 2014, 10, S390-S394.e2.		58
139	Development and validation of dried matrix spot sampling for the quantitative determination of amyloid β peptides in cerebrospinal fluid. <i>Clinical Chemistry and Laboratory Medicine</i> , 2014, 52, 649-55.	1.4	8
140	An innovative biologic recycling process of leukoreduction filters to produce active human antimicrobial peptides. <i>Transfusion</i> , 2014, 54, 1332-1339.	0.8	6
141	Relationship between genome and epigenome - challenges and requirements for future research. <i>BMC Genomics</i> , 2014, 15, 487.	1.2	24
142	Clinical measurement of Hepcidin-25 in human serum: Is quantitative mass spectrometry up to the job?. <i>EuPA Open Proteomics</i> , 2014, 3, 60-67.	2.5	19
143	Initial Memory Deficit Profiles in Patients with a Cerebrospinal Fluid Alzheimer's Disease Signature. <i>Journal of Alzheimer's Disease</i> , 2014, 41, 1109-1116.	1.2	11
144	O1-09-02: DETECTION AND QUANTIFICATION OF THE TAU PROTEIN AND ITS ISOFORMS IN THE CSF OF ALZHEIMER'S DISEASE PATIENTS USING MASS SPECTROMETRY. , 2014, 10, P147-P147.		0

#	ARTICLE	IF	CITATIONS
145	Systems Medicine Approaches for the Definition of Complex Phenotypes in Chronic Diseases and Ageing. From Concept to Implementation and Policies. <i>Current Pharmaceutical Design</i> , 2014, 20, 5928-5944.	0.9	63
146	Exacerbated CSF abnormalities in younger patients with Alzheimer's disease. <i>Neurobiology of Disease</i> , 2013, 54, 486-491.	2.1	14
147	Biomarkers of Alzheimer's disease: The present and the future. <i>Revue Neurologique</i> , 2013, 169, 719-723.	0.6	12
148	Comparative analysis of protein expression of three stem cell populations: Models of cytokine delivery system in vivo. <i>International Journal of Pharmaceutics</i> , 2013, 440, 72-82.	2.6	42
149	Intersite variability of CSF Alzheimer's disease biomarkers in clinical setting. <i>Alzheimer's and Dementia</i> , 2013, 9, 406-413.	0.4	63
150	Prion Replication Occurs in Endogenous Adult Neural Stem Cells and Alters Their Neuronal Fate: Involvement of Endogenous Neural Stem Cells in Prion Diseases. <i>PLoS Pathogens</i> , 2013, 9, e1003485.	2.1	27
151	Performance evaluation of human cytokines profiles obtained by various multiplexed-based technologies underlines a need for standardization. <i>Clinical Chemistry and Laboratory Medicine</i> , 2013, 51, 1385-93.	1.4	24
152	Current and future use of "dried blood spot" analyses in clinical chemistry. <i>Clinical Chemistry and Laboratory Medicine</i> , 2013, 51, 1897-1909.	1.4	102
153	Quantitative Clinical Chemistry Proteomics (qCCP) using mass spectrometry: general characteristics and application. <i>Clinical Chemistry and Laboratory Medicine</i> , 2013, 51, 919-35.	1.4	47
154	Impact of the 2008-2012 French Alzheimer Plan on the Use of Cerebrospinal Fluid Biomarkers in Research Memory Center: The PLM Study. <i>Journal of Alzheimer's Disease</i> , 2013, 34, 297-305.	1.2	51
155	Recombinant Human Prion Protein Inhibits Prion Propagation in vitro. <i>Scientific Reports</i> , 2013, 3, 2911.	1.6	27
156	From "Clinical Proteomics" to "Clinical Chemistry Proteomics": considerations using quantitative mass-spectrometry as a model approach. <i>Clinical Chemistry and Laboratory Medicine</i> , 2012, 50, 235-42.	1.4	7
157	Cerebrospinal Fluid Collection Tubes: A Critical Issue for Alzheimer Disease Diagnosis. <i>Clinical Chemistry</i> , 2012, 58, 787-789.	1.5	50
158	Interest of CSF biomarker analysis in possible cerebral amyloid angiopathy cases defined by the modified Boston criteria. <i>Journal of Neurology</i> , 2012, 259, 2429-2433.	1.8	65
159	Risk of Alzheimer's Disease Biological Misdiagnosis Linked to Cerebrospinal Collection Tubes. <i>Journal of Alzheimer's Disease</i> , 2012, 31, 13-20.	1.2	94
160	Transcriptomic and proteomic analyses of human endometrial receptivity under natural cycle. <i>Fertility and Sterility</i> , 2012, 98, S226.	0.5	0
161	Recommendations to standardize preanalytical confounding factors in Alzheimer's and Parkinson's disease cerebrospinal fluid biomarkers: an update. <i>Biomarkers in Medicine</i> , 2012, 6, 419-430.	0.6	280
162	Rejuvenating senescent and centenarian human cells by reprogramming through the pluripotent state. <i>Genes and Development</i> , 2011, 25, 2248-2253.	2.7	444

#	ARTICLE	IF	CITATIONS
163	Decreased sA β 2PP β , A β 238, and A β 240 Cerebrospinal Fluid Levels in Frontotemporal Dementia. <i>Journal of Alzheimer's Disease</i> , 2011, 26, 553-563.	1.2	65
164	Stem Cell Therapy Extends Incubation and Survival Time in Prion-Infected Mice in a Time Windowâ€“Dependant Manner. <i>Journal of Infectious Diseases</i> , 2011, 204, 1038-1045.	1.9	23
165	HEPES inhibits the conversion of prion protein in cell culture. <i>Journal of General Virology</i> , 2011, 92, 1244-1250.	1.3	4
166	Oligomeric-Induced Activity by Thienyl Pyrimidine Compounds Traps Prion Infectivity. <i>Journal of Neuroscience</i> , 2011, 31, 14882-14892.	1.7	18
167	Two Dimensional Gel Electrophoresis Analysis of Mesenchymal Stem Cells. <i>Methods in Molecular Biology</i> , 2011, 698, 431-442.	0.4	3
168	Production of a monoclonal antibody, against human I β -synuclein, in a subpopulation of C57BL/6J mice, presenting a deletion of the I β -synuclein locus. <i>Journal of Neuroscience Methods</i> , 2010, 192, 268-276.	1.3	11
169	Standard Preanalytical Coding for Biospecimens: Defining the Sample PREanalytical Code. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2010, 19, 1004-1011.	1.1	166
170	Proteomic consequences of expression and pathological conversion of the prion protein in inducible neuroblastoma N2a cells. <i>Prion</i> , 2010, 4, 292-301.	0.9	13
171	Correlations between soluble I β /I β 2 forms of amyloid precursor protein and A β 238, 40, and 42 in human cerebrospinal fluid. <i>Brain Research</i> , 2010, 1357, 175-183.	1.1	69
172	Human Biospecimen Research: Experimental Protocol and Quality Control Tools. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2009, 18, 1017-1025.	1.1	103
173	New hospital disinfection processes for both conventional and prion infectious agents compatible with thermosensitive medical equipment. <i>Journal of Hospital Infection</i> , 2009, 72, 342-350.	1.4	33
174	Comparative proteomic analysis of human mesenchymal and embryonic stem cells: Towards the definition of a mesenchymal stem cell proteomic signature. <i>Proteomics</i> , 2009, 9, 223-232.	1.3	82
175	Depletion of one, six, twelve or twenty major blood proteins before proteomic analysis: The more the better?. <i>Journal of Proteomics</i> , 2009, 72, 945-951.	1.2	89
176	Prion Protein Expression and Processing in Human Mononuclear Cells: The Impact of the Codon 129 Prion Gene Polymorphism. <i>PLoS ONE</i> , 2009, 4, e5796.	1.1	4
177	The Role of the Prion Protein in the Molecular Basis for Synaptic Plasticity and Nervous System Development. <i>Journal of Molecular Neuroscience</i> , 2008, 34, 9-15.	1.1	8
178	Genetic heterogeneity versus molecular analysis of prion susceptibility in neuroblasma N2a sublines. <i>Archives of Virology</i> , 2008, 153, 1693-1702.	0.9	11
179	Clinical proteomics of the cerebrospinal fluid: Towards the discovery of new biomarkers. <i>Proteomics - Clinical Applications</i> , 2008, 2, 428-436.	0.8	88
180	A new genetic algorithm in proteomics: Feature selection for SELDI-TOF data. <i>Computational Statistics and Data Analysis</i> , 2008, 52, 4380-4394.	0.7	11

#	ARTICLE	IF	CITATIONS
181	Important research questions in allergy and related diseases: nonallergic rhinitis: a GA ² LEN paper. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2008, 63, 842-853.	2.7	158
182	Cell specific differences between human adipose-derived and mesenchymal stromal cells despite similar differentiation potentials. <i>Experimental Cell Research</i> , 2008, 314, 1575-1584.	1.2	316
183	Mouse neuroblastoma cells release prion infectivity associated with exosomal vesicles. <i>Biology of the Cell</i> , 2008, 100, 603-618.	0.7	124
184	Trehalose impairs aggregation of PrPSc molecules and protects prion-infected cells against oxidative damage. <i>Biochemical and Biophysical Research Communications</i> , 2008, 374, 44-48.	1.0	76
185	Autoantibody profiling on high-density protein microarrays for biomarker discovery in the cerebrospinal fluid. <i>Journal of Immunological Methods</i> , 2008, 338, 75-78.	0.6	11
186	Functional, molecular and proteomic characterisation of bone marrow mesenchymal stem cells in rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2008, 67, 741-749.	0.5	139
187	Prions Impair Bioaminergic Functions through Serotonin- or Catecholamine-derived Neurotoxins in Neuronal Cells. <i>Journal of Biological Chemistry</i> , 2008, 283, 23782-23790.	1.6	21
188	Cellular pathogenesis in prion diseases. <i>Veterinary Research</i> , 2008, 39, 44.	1.1	20
189	Cyclodextrins Inhibit Replication of Scrapie Prion Protein in Cell Culture. <i>Journal of Virology</i> , 2007, 81, 11195-11207.	1.5	39
190	Proteomics of primary mesenchymal stem cells. <i>Regenerative Medicine</i> , 2006, 1, 511-517.	0.8	21
191	Neural Stem Cell Model for Prion Propagation. <i>Stem Cells</i> , 2006, 24, 2284-2291.	1.4	37
192	Interest of major serum protein removal for Surface-Enhanced Laser Desorption/Ionization - Time Of Flight (SELDI-TOF) proteomic blood profiling. <i>Proteome Science</i> , 2006, 4, 20.	0.7	35
193	The truncated 23-230 form of the prion protein localizes to the nuclei of inducible cell lines independently of its nuclear localization signals and is not cytotoxic. <i>Molecular and Cellular Neurosciences</i> , 2006, 32, 315-323.	1.0	23
194	Retrovirus infection strongly enhances scrapie infectivity release in cell culture. <i>EMBO Journal</i> , 2006, 25, 2674-2685.	3.5	112
195	Comparison between surface and bead-based MALDI profiling technologies using a single bioinformatics algorithm. <i>Clinical Proteomics</i> , 2006, 2, 145-152.	1.1	1
196	A Novel Copper-Hydrogen Peroxide Formulation for Prion Decontamination. <i>Journal of Infectious Diseases</i> , 2006, 194, 865-869.	1.9	22
197	Prion Propagation in Cell Culture. , 2005, 299, 227-234.		8
198	Heat Shock Affects Trafficking of DAX-1 by Inducing Its Rapid and Reversible Cytoplasmic Localization. <i>Endocrine</i> , 2005, 28, 137-144.	2.2	6

#	ARTICLE	IF	CITATIONS
199	The scrapie prion protein is present in flotillin-1-positive vesicles in central- but not peripheral-derived neuronal cell lines. <i>European Journal of Neuroscience</i> , 2005, 21, 2063-2072.	1.2	62
200	Biological and Biochemical Characteristics of Prion Strains Conserved in Persistently Infected Cell Cultures. <i>Journal of Virology</i> , 2005, 79, 7104-7112.	1.5	36
201	Screening of 145 Anti-PrP Monoclonal Antibodies for Their Capacity to Inhibit PrPSc Replication in Infected Cells. <i>Journal of Biological Chemistry</i> , 2005, 280, 11247-11258.	1.6	272
202	Elevated plasma cysteinylglycine levels caused by cilastatin-associated antibiotic treatment. <i>Clinical Chemistry and Laboratory Medicine</i> , 2005, 43, 332-4.	1.4	8
203	Inhibition of PrPSc formation by lentiviral gene transfer of PrP containing dominant negative mutations. <i>Journal of Cell Science</i> , 2004, 117, 5591-5597.	1.2	40
204	Cationic phosphorus-containing dendrimers reduce prion replication both in cell culture and in mice infected with scrapie. <i>Journal of General Virology</i> , 2004, 85, 1791-1799.	1.3	172
205	Scrapie-like prion protein is translocated to the nuclei of infected cells independently of proteasome inhibition and interacts with chromatin. <i>Journal of Cell Science</i> , 2004, 117, 2411-2416.	1.2	78
206	Anti-PrP antibodies block PrPSc replication in prion-infected cell cultures by accelerating PrPC degradation. <i>Journal of Neurochemistry</i> , 2004, 89, 454-463.	2.1	111
207	Prion protein protects against DNA damage induced by paraquat in cultured cells. <i>Free Radical Biology and Medicine</i> , 2004, 37, 1224-1230.	1.3	47
208	Alpha- and beta- cleavages of the amino-terminus of the cellular prion protein. <i>Biology of the Cell</i> , 2004, 96, 125-132.	0.7	150
209	Prion protein suppresses perturbation of cellular copper homeostasis under oxidative conditions. <i>Biochemical and Biophysical Research Communications</i> , 2004, 313, 850-855.	1.0	38
210	Detection of prion after decontamination procedures: comparative study of standard Western blot, filter retention and scrapie-cell assay. <i>Journal of Hospital Infection</i> , 2004, 57, 156-161.	1.4	17
211	Determination of plasma amino acids by fluorescent derivatization and reversed-phase liquid chromatographic separation. <i>Clinical Laboratory</i> , 2004, 50, 153-8.	0.2	5
212	Prion-like protein Doppel expression is not modified in scrapie-infected cells and in the brains of patients with Creutzfeldt-Jakob disease. <i>FEBS Letters</i> , 2003, 536, 61-65.	1.3	18
213	Prion protein as trans-interacting partner for neurons is involved in neurite outgrowth and neuronal survival. <i>Molecular and Cellular Neurosciences</i> , 2003, 22, 227-233.	1.0	164
214	Structure-function analysis reveals the molecular determinants of the impaired biological function of DAX-1 mutants in AHC patients. <i>Human Molecular Genetics</i> , 2003, 12, 1063-1072.	1.4	44
215	Prion propagation in cultured cells. <i>British Medical Bulletin</i> , 2003, 66, 87-97.	2.7	77
216	Prion Infection Impairs Copper Binding of Cultured Cells. <i>Journal of Biological Chemistry</i> , 2003, 278, 14595-14598.	1.6	54

#	ARTICLE	IF	CITATIONS
217	Expression of Prion Protein Increases Cellular Copper Binding and Antioxidant Enzyme Activities but Not Copper Delivery. <i>Journal of Biological Chemistry</i> , 2003, 278, 9064-9072.	1.6	173
218	From Chemical Drug to Immunotherapy: New Approaches for the Treatment of Prion Diseases. <i>Current Medicinal Chemistry Immunology, Endocrine & Metabolic Agents</i> , 2003, 3, 199-205.	0.2	1
219	Filipin Prevents Pathological Prion Protein Accumulation by Reducing Endocytosis and Inducing Cellular PrP Release. <i>Journal of Biological Chemistry</i> , 2002, 277, 25457-25464.	1.6	126
220	Stimulation of PrPC Retrograde Transport toward the Endoplasmic Reticulum Increases Accumulation of PrPSc in Prion-infected Cells. <i>Journal of Biological Chemistry</i> , 2002, 277, 38972-38977.	1.6	98
221	X-linked adrenal hypoplasia congenita is caused by abnormal nuclear localization of the DAX-1 protein. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2002, 99, 8225-8230.	3.3	46
222	The Human "Prion-like" Protein Doppel Is Expressed in Both Sertoli Cells and Spermatozoa. <i>Journal of Biological Chemistry</i> , 2002, 277, 43071-43078.	1.6	75
223	PrP Expression and Replication by Schwann Cells: Implications in Prion Spreading. <i>Journal of Virology</i> , 2002, 76, 2434-2439.	1.5	72
224	PrP-dependent cell adhesion in N2a neuroblastoma cells. <i>FEBS Letters</i> , 2002, 514, 159-162.	1.3	81
225	BSE infection of the small short-lived primate <i>Microcebus murinus</i> . <i>Comptes Rendus - Biologies</i> , 2002, 325, 67-74.	0.1	10
226	From stem cells to prion signalling. <i>Comptes Rendus - Biologies</i> , 2002, 325, 9-15.	0.1	2
227	Oxidative stress and the prion protein in transmissible spongiform encephalopathies. <i>Brain Research Reviews</i> , 2002, 38, 328-339.	9.1	167
228	La Protéine du Prion. <i>Société De Biologie Journal</i> , 2002, 196, 309-312.	0.3	2
229	Metal ions and prion diseases. <i>Current Opinion in Chemical Biology</i> , 2002, 6, 187-192.	2.8	105
230	Brain and buffy coat transmission of bovine spongiform encephalopathy to the primate <i>Microcebus murinus</i> . <i>Transfusion</i> , 2002, 42, 513-516.	0.8	52
231	Cell Culture Models of Transmissible Spongiform Encephalopathies. <i>Biochemical and Biophysical Research Communications</i> , 2001, 289, 311-316.	1.0	28
232	Effect of Amphotericin B on Wild-Type and Mutated Prion Proteins in Cultured Cells. <i>Journal of Neurochemistry</i> , 2001, 74, 754-762.	2.1	25
233	Effect of Congo Red on Wild-Type and Mutated Prion Proteins in Cultured Cells. <i>Journal of Neurochemistry</i> , 2001, 74, 222-230.	2.1	35
234	Ex vivo propagation of infectious sheep scrapie agent in heterologous epithelial cells expressing ovine prion protein. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2001, 98, 4055-4059.	3.3	203

#	ARTICLE	IF	CITATIONS
235	Cleavage of the Amino Terminus of the Prion Protein by Reactive Oxygen Species. <i>Journal of Biological Chemistry</i> , 2001, 276, 2286-2291.	1.6	154
236	Glycosylation of prions and its effects on protein conformation relevant to amino acid mutations. <i>Journal of Molecular Graphics and Modelling</i> , 2000, 18, 126-134.	1.3	22
237	Amphotericin B Inhibits the Generation of the Scrapie Isoform of the Prion Protein in Infected Cultures. <i>Journal of Virology</i> , 2000, 74, 3135-3140.	1.5	112
238	Successful Transmission of Three Mouse-Adapted Scrapie Strains to Murine Neuroblastoma Cell Lines Overexpressing Wild-Type Mouse Prion Protein. <i>Journal of Virology</i> , 2000, 74, 320-325.	1.5	220
239	Prion infection impairs the cellular response to oxidative stress. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2000, 97, 13937-13942.	3.3	203
240	Phorbol Ester-regulated Cleavage of Normal Prion Protein in HEK293 Human Cells and Murine Neurons. <i>Journal of Biological Chemistry</i> , 2000, 275, 35612-35616.	1.6	98
241	Signal Transduction Through Prion Protein. <i>Science</i> , 2000, 289, 1925-1928.	6.0	701
242	Trafficking of the cellular isoform of the prion protein. <i>Biomedicine and Pharmacotherapy</i> , 1999, 53, 39-46.	2.5	19
243	Familial Prion Diseases Modeled in Cell Culture. , 1998, , 87-98.		0
244	Blockade of Glycosylation Promotes Acquisition of Scrapie-like Properties by the Prion Protein in Cultured Cells. <i>Journal of Biological Chemistry</i> , 1997, 272, 21479-21487.	1.6	163
245	Evidence for a Six-transmembrane Domain Structure of Presenilin 1. <i>Journal of Biological Chemistry</i> , 1997, 272, 12047-12051.	1.6	143
246	Identification of Intermediate Steps in the Conversion of a Mutant Prion Protein to a Scrapie-like Form in Cultured Cells. <i>Journal of Biological Chemistry</i> , 1997, 272, 11604-11612.	1.6	84
247	A wild-type prion protein does not acquire properties of the scrapie isoform when coexpressed with a mutant prion protein in cultured cells. <i>Molecular Brain Research</i> , 1997, 52, 139-145.	2.5	13
248	Two mutant prion proteins expressed in cultured cells acquire biochemical properties reminiscent of the scrapie isoform.. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1996, 93, 5610-5614.	3.3	98
249	Mutant and Infectious Prion Proteins Display Common Biochemical Properties in Cultured Cells. <i>Journal of Biological Chemistry</i> , 1996, 271, 1633-1637.	1.6	128
250	Le rôle de la protéine du prion dans les encéphalopathies spongiformes transmissibles humaines.. <i>Medecine/Sciences</i> , 1996, 12, 949.	0.0	4
251	Sulfated Glycans Stimulate Endocytosis of the Cellular Isoform of the Prion Protein, PrPC, in Cultured Cells. <i>Journal of Biological Chemistry</i> , 1995, 270, 30221-30229.	1.6	538
252	A Mutant Prion Protein Displays an Aberrant Membrane Association When Expressed in Cultured Cells. <i>Journal of Biological Chemistry</i> , 1995, 270, 24589-24597.	1.6	141

#	ARTICLE	IF	CITATIONS
253	An endogenous lectin and its glycoprotein ligands are triggering basal and axon-induced Schwann cell proliferation. <i>Glycobiology</i> , 1995, 5, 371-383.	1.3	13
254	Differential expression of an endogenous mannose-binding protein R1 during muscle development and regeneration delineating its role in myoblast fusion. <i>Glycobiology</i> , 1994, 4, 23-38.	1.3	9
255	Presence of anti-CSL antibodies in the cerebrospinal fluid of patients: A sensitive and specific test in the diagnosis of multiple sclerosis. <i>Journal of Neuroimmunology</i> , 1994, 52, 175-182.	1.1	14
256	Cellular processing of normal and mutant mammalian prion proteins. <i>Neurobiology of Aging</i> , 1994, 15, S87-S88.	1.5	29
257	Neurite outgrowth of neurons of rat dorsal root ganglia induced by new neurotrophic substances with guanidine group. <i>Neuroscience Letters</i> , 1993, 152, 57-60.	1.0	8
258	Lesion-induced re-expression of neonatal recognition molecules in adult rat cerebellum. <i>Brain Research Bulletin</i> , 1993, 30, 515-521.	1.4	18
259	Cerebellar Lectins. <i>International Review of Cytology</i> , 1992, 135, 123-154.	6.2	7
260	Cerebrospinal fluid anti-cerebellar soluble lectin antibodies in human immunodeficiency virus type 1 infection. <i>Journal of Neuroimmunology</i> , 1992, 36, 245-249.	1.1	10
261	Glycoproteins and lectins in cell adhesion and cell recognition processes. <i>The Histochemical Journal</i> , 1992, 24, 791-804.	0.6	42
262	Endogenous Lectin Cerebellar Soluble Lectin Involved in Myelination Is Absent from Nonmyelinating Schwann Cells. <i>Journal of Neurochemistry</i> , 1992, 58, 1768-1772.	2.1	10
263	Brain Lectins:Structure and Function.. <i>Trends in Glycoscience and Glycotechnology</i> , 1992, 4, 415-426.	0.0	3
264	An endogenous lectin and one of its neuronal glycoprotein ligands are involved in contact guidance of neuron migration.. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1990, 87, 6455-6459.	3.3	46
265	Antibodies to cerebellar soluble lectin CSL in multiple sclerosis. <i>Lancet, The</i> , 1990, 335, 1482-1484.	6.3	25
266	Location of a transiently expressed glycoprotein in developing cerebellum delineating its possible ontogenetic roles. <i>Neuroscience</i> , 1989, 33, 111-124.	1.1	42
267	Ex Vivo Transmission of Mouse-Adapted Prion Strains to N2a and GT1-7 Cell Lines. , 0, , 679-686.		2
268	Comparison of Hydrophobic, Lipophilic and Immunodepletion Pre- Fractionation Methods for Label-Free LC-MS/MS Identification of Biomarkers in Human Cerebrospinal Fluid. <i>Journal of Proteomics and Bioinformatics</i> , 0, s5, .	0.4	2